ZOMEDICA CORP (ZOM) Fundamental Analysis & Valuation

NYSEARCA:ZOM • CA98980M1095

Current stock price

0.0973 USD
0 (-0.21%)
Last:

This ZOM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ZOM Profitability Analysis

1.1 Basic Checks

  • In the past year ZOM has reported negative net income.
  • In the past year ZOM has reported a negative cash flow from operations.
  • In the past 5 years ZOM always reported negative net income.
  • ZOM had a negative operating cash flow in each of the past 5 years.
ZOM Yearly Net Income VS EBIT VS OCF VS FCFZOM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

  • ZOM has a Return On Assets of -29.05%. This is comparable to the rest of the industry: ZOM outperforms 43.16% of its industry peers.
  • ZOM has a Return On Equity (-30.66%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -29.05%
ROE -30.66%
ROIC N/A
ROA(3y)-8.76%
ROA(5y)-104.96%
ROE(3y)-9.18%
ROE(5y)-199.7%
ROIC(3y)N/A
ROIC(5y)N/A
ZOM Yearly ROA, ROE, ROICZOM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600 -800

1.3 Margins

  • ZOM has a Gross Margin of 69.64%. This is in the better half of the industry: ZOM outperforms 79.47% of its industry peers.
  • The Profit Margin and Operating Margin are not available for ZOM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.64%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZOM Yearly Profit, Operating, Gross MarginsZOM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300 -400 -500

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. ZOM Health Analysis

2.1 Basic Checks

  • ZOM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ZOM remains at a similar level compared to 1 year ago.
  • There is no outstanding debt for ZOM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ZOM Yearly Shares OutstandingZOM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M
ZOM Yearly Total Debt VS Total AssetsZOM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

  • ZOM has an Altman-Z score of 3.68. This indicates that ZOM is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of ZOM (3.68) is better than 72.63% of its industry peers.
  • ZOM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.68
ROIC/WACCN/A
WACC8.9%
ZOM Yearly LT Debt VS Equity VS FCFZOM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M

2.3 Liquidity

  • A Current Ratio of 10.82 indicates that ZOM has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 10.82, ZOM belongs to the top of the industry, outperforming 92.63% of the companies in the same industry.
  • ZOM has a Quick Ratio of 10.15. This indicates that ZOM is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 10.15, ZOM belongs to the top of the industry, outperforming 92.63% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.82
Quick Ratio 10.15
ZOM Yearly Current Assets VS Current LiabilitesZOM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. ZOM Growth Analysis

3.1 Past

  • The earnings per share for ZOM have decreased strongly by -57.89% in the last year.
  • The Revenue has grown by 11.33% in the past year. This is quite good.
EPS 1Y (TTM)-57.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-900%
Revenue 1Y (TTM)11.33%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%10.29%

3.2 Future

  • ZOM is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -7.13% yearly.
  • The Revenue is expected to grow by 23.91% on average over the next years. This is a very strong growth
EPS Next Y-110.78%
EPS Next 2Y-14.78%
EPS Next 3Y-5.84%
EPS Next 5Y-7.13%
Revenue Next Year10.67%
Revenue Next 2Y19.02%
Revenue Next 3Y22.19%
Revenue Next 5Y23.91%

3.3 Evolution

ZOM Yearly Revenue VS EstimatesZOM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M 40M 50M
ZOM Yearly EPS VS EstimatesZOM Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2022 2023 2024 2025 2026 2027 -0.05 -0.1 -0.15

More info and screens

Find the best growth stocksShow best growing peers

0

4. ZOM Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ZOM. In the last year negative earnings were reported.
  • Also next year ZOM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZOM Price Earnings VS Forward Price EarningsZOM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZOM Per share dataZOM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 0.1 0.15 0.2

4.3 Compensation for Growth

  • A cheap valuation may be justified as ZOM's earnings are expected to decrease with -5.84% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.78%
EPS Next 3Y-5.84%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ZOM Dividend Analysis

5.1 Amount

  • No dividends for ZOM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

ZOM Fundamentals: All Metrics, Ratios and Statistics

ZOMEDICA CORP

NYSEARCA:ZOM (3/4/2025, 8:08:11 PM)

0.0973

0 (-0.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-13
Earnings (Next)05-07
Inst Owners9.39%
Inst Owner Change-30.34%
Ins Owners0.74%
Ins Owner Change0%
Market Cap95.35M
Revenue(TTM)26.73M
Net Income(TTM)-62.19M
Analysts80
Price Target0.26 (167.21%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-23.83%
Min Revenue beat(2)-27.36%
Max Revenue beat(2)-20.3%
Revenue beat(4)1
Avg Revenue beat(4)-17.04%
Min Revenue beat(4)-27.36%
Max Revenue beat(4)3.78%
Revenue beat(8)1
Avg Revenue beat(8)-16.36%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-380%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-19.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.57
P/FCF N/A
P/OCF N/A
P/B 0.47
P/tB 0.9
EV/EBITDA N/A
EPS(TTM)-0.03
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0.03
BVpS0.21
TBVpS0.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -29.05%
ROE -30.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.64%
FCFM N/A
ROA(3y)-8.76%
ROA(5y)-104.96%
ROE(3y)-9.18%
ROE(5y)-199.7%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 86.87%
Cap/Sales 25.37%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.82
Quick Ratio 10.15
Altman-Z 3.68
F-Score4
WACC8.9%
ROIC/WACCN/A
Cap/Depr(3y)120.38%
Cap/Depr(5y)90.3%
Cap/Sales(3y)29.66%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-57.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-900%
EPS Next Y-110.78%
EPS Next 2Y-14.78%
EPS Next 3Y-5.84%
EPS Next 5Y-7.13%
Revenue 1Y (TTM)11.33%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%10.29%
Revenue Next Year10.67%
Revenue Next 2Y19.02%
Revenue Next 3Y22.19%
Revenue Next 5Y23.91%
EBIT growth 1Y-50.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-88.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-70%
OCF growth 3YN/A
OCF growth 5YN/A

ZOMEDICA CORP / ZOM Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ZOMEDICA CORP?

ChartMill assigns a fundamental rating of 3 / 10 to ZOM.


Can you provide the valuation status for ZOMEDICA CORP?

ChartMill assigns a valuation rating of 0 / 10 to ZOMEDICA CORP (ZOM). This can be considered as Overvalued.


What is the profitability of ZOM stock?

ZOMEDICA CORP (ZOM) has a profitability rating of 1 / 10.